ZypAdhera ® (olanzapine pamoate monohydrate)
Severe acute respiratory syndrome coronavirus 2 is an emerging virus that has caused the recent COVID-19 pandemic.1 Recently, vaccines have been developed against SARS-CoV-2 and additional vaccines are expected to be available in the coming months.2
SARS-CoV-2 Vaccination With Olanzapine Long-acting Injection
The use of a SARS-CoV-2 vaccine in patients treated with olanzapine pamoate has not been studied by Lilly.
Decisions regarding the use of any vaccination, including SARS-CoV-2 vaccines, in patients treated with olanzapine pamoate should be made at the discretion of the prescribing physician using their best clinical judgment, and must be made by the clinician after careful consideration of risk factors of the patient as well as the risks and benefits of vaccination. Consultation with an infectious disease expert may be helpful in high-risk or emergency situations such as the current COVID-19 pandemic.
1. Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237. https://doi.org/10.1038/s41392-020-00352-y
2. Su Z, Wen J, McDonnell D, et al. Vaccines are not yet a silver bullet: The imperative of continued communication about the importance of COVID-19 safety measures. Brain Behav Immun Health. 2021;12:100204. https://doi.org/10.1016/j.bbih.2021.100204
COVID-19 = coronavirus disease 2019
LAI = long-acting injection
Lilly = Eli Lilly and Company
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
Date of Last Review: January 15, 2021